Quarterly Outlook
Macro Outlook: The US rate cut cycle has begun
Peter Garnry
Chief Investment Strategist
Markets have been moving this week after Beijing announced its biggest stimulus since the pandemic in an effort to re-ignite the economic slowdown and subsequent deflation which has plagued China - one of the world largest economies - for a while. Global equities & Precious metals seemed to overall welcome the news with several sectors rallying, especially luxury groups LVMH & Kering trading up on optimism that the stimulus might revive otherwise weakened demand. The Yen has been on a rollercoaster session ahead of Japan's LDP vote and hiking process pressures, and we saw danish pharma giant Novo-Nordisk hit a 6-month low on concerns over competition and pricing. Read more about this week's key stories below:
Hang Seng leaps as China adds to stimulus
After months of economic weakness and speculation the PBOC stepped in and took a more aggressive approach with a number of measures in support of the economy as well as the stock market. This includes among other cutting the 7-day reverse repo rate cut by 20bps, cutting the MLF by 30bps, lower mortgage rates doe existing loads and 500B yuan liquidity support for Chinese stocks. This added on to the risk sentiment that gave way following a 50bps cut by Fed. At Saxo we saw this translated into an increase in number of clients exposed to Hong Kong index by some 10% with 77% of clients being long.
China’s Bold Stimulus Measures: What It Means for Markets
Novo Nordisk pressured on pricing
Novo Nordisk share price hit a 6-month low and is down almost 20% over the last 10 weeks following the slightly disappointing Q2 results. This week CEO Lars Fruergaard testified in front of the US Senate health committee and that gave rise to more drug-pricing headline noise. Fruergaard promised price cuts, but only if the benefit goes to consumers and not the insurance companies. However, Novo Nordisk continue to hold massive longer term potential and key stock price catalyst in the near term include Rybelsus cardiovascular data and late-stage CagriSema data, which is key to upholding the obesity lead vs. Eli Lilly.
Yen surge after Japan PM election
The yen surged to the upper 142 range against the U.S. dollar after Shigeru Ishiba won Japan's ruling party election, defeating Sanae Takaichi. Ishiba's victory, which positions him to become Japan's next prime minister, led to a brief jump in JPY . Ishiba supports normalizing Japan's monetary policy, causing the yen to strengthen and raising concerns in the stock market due to his stance on financial income taxation.
Next week markets will be monitoring key US jobdata incl. Jobless/continuing claims (Thu), general unemployment & non-farm payrolls (Fri), while also keeping an eye at German inflation data (Mon) & euro area core cpi estimates (Tue). Sports-retail giant Nike that recently named a new CEO is expected to release Q1 25 earnings on Tuesday.
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)